Skip to main content
Full access
Letter
Published Online: 1 February 1999

Mirtazapine-Induced Mania in a Case of Poststroke Depression

Publication: The Journal of Neuropsychiatry and Clinical Neurosciences
SIR: Safety information available on the noradrenergic and specific serotonergic antidepressant mirtazapine indicates that a manic switch is a rare event. This adverse reaction occurred in 0.25% of all mirtazapine-treated patients during the worldwide clinical trial program.1 We report a case of a patient who switched from a prolonged and refractory poststroke depression to an acute manic excitement shortly after initiating treatment with mirtazapine.

Case Report

A 68-year-old man had a right hemisphere stroke 2 years before being referred by his neurologist for psychiatric treatment. The patient was withdrawn and neglectful of his personal hygiene, he had poor appetite, and his sleep was interrupted by early-morning awakening. He also had memory difficulties and became lost in familiar surroundings. The initial examination revealed a disheveled individual who was oriented only to person. His speech was fluent and coherent, but he was slow to respond. Memory for recent events was impaired. He expressed feelings of worthlessness and helplessness and passive death wishes. Mini-Mental State Examination score was 17. He presented mild residual left-side weakness. He had no previous history of depression. Medical history was positive for insulin-dependent diabetes mellitus, coronary artery disease, and hypertension. Brain MRI revealed ischemic events in anterior portion of right frontal lobe and deep right temporal lobe. He had failed adequate trials of fluoxetine (titrated up to 60 mg daily for 5 months) and paroxetine (titrated up to 60 mg daily for 4 months). Paroxetine was discontinued, and after a washout of 10 days we initiated mirtazapine 15 mg at bedtime. Hamilton Rating Scale for Depression score was 27 before mirtazapine treatment. Three days later he became agitated, showing pressured speech and decreased need for sleep. The family reported that the patient went out in the streets without proper clothing and walked for miles without stopping. After returning home he refused insulin injections, accused his wife of having an affair, and became physically aggressive. He was subsequently admitted to our neuropsychiatric service and mirtazapine was discontinued. Treatment with carbamazepine and haloperidol was instituted, with gradual abatement of his manic excitement.
It is unclear what role mirtazapine played in the development of mania in this patient. A case of hypomania associated with mirtazapine augmentation of sertraline has been reported.2 In our case, previous paroxetine treatment is unlikely to be related to this untoward effect because of the 10-day washout period before mirtazapine initiation. Probably mirtazapine, by virtue of its alpha-2 antagonism, induced a significant increment in biogenic amine turnover that released dorsal cortical and limbic areas from tonic inhibition caused by right hemisphere lesion.
This case suggests that mirtazapine treatment of right hemisphere poststroke depression should be approached with caution.

References

1.
Montgomery SA: Safety of mirtazapine: a review. Int Clin Psychopharmacology 1995; 10(suppl 4):37–45
2.
Soutullo CA, McElroy SL, Keck PE: Hypomania associated with mirtazapine augmentation of sertraline (letter). J Clin Psychiatry 1998; 59:320

Information & Authors

Information

Published In

Go to The Journal of Neuropsychiatry and Clinical Neurosciences
Go to The Journal of Neuropsychiatry and Clinical Neurosciences
The Journal of Neuropsychiatry and Clinical Neurosciences
Pages: 115 - 116
PubMed: 9990568

History

Published online: 1 February 1999
Published in print: February 1999

Authors

Affiliations

Ovidio A. De León, M.D.
Department of Psychiatry, University of Illinois College of Medicine, Chicago, IL
Kevin M. Furmaga, Pharm.D.
Department of Pharmacy Practice, University of Illinois College of Pharmacy, and Department of Psychiatry, University of Illinois College of Medicine, Chicago, IL
Juliana Kaltsounis, Pharm.D.
Department of Pharmacy Practice, University of Illinois College of Pharmacy, Chicago, IL

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

There are no citations for this item

View Options

View options

PDF/ePub

View PDF/ePub

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - Journal of Neuropsychiatry and Clinical Neurosciences

PPV Articles - Journal of Neuropsychiatry and Clinical Neurosciences

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share